Ravulizumab and its impact on neuromyelitis optica
Treatments studied
Part of Brain & nervous system, Eyes & vision, Immune system & allergy clinical trials.
This study looks at how well ravulizumab (Ultomiris) works for people with neuromyelitis optica spectrum disorder (NMOSD) by tracking symptoms and MRI scans over time. It aims to see if the drug helps control the disease in real-world use.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have a confirmed diagnosis of neuromyelitis optica spectrum disorder and test positive for aquaporin-4 antibodies
- You are currently taking ravulizumab (Ultomiris) as your doctor prescribed
- Your disability level is not too severe (score under 7 on the Expanded Disability Status Scale)
- You are not currently taking part in another NMOSD drug study
- You are not pregnant or breastfeeding, and have no active infection or unresolved meningococcal disease
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new treatment called CC-97540 (a type of CAR T-cell therapy) for people with neuromyelitis optica spectrum disorder (NMOSD), which is an autoimmune disease that affects the eyes and spinal cord. The goal is to see if this treatment is safe and tolerable.
This study tests a new medicine called ravulizumab (an infusion) to reduce relapses in people with neuromyelitis optica spectrum disorder (NMOSD), a rare condition affecting the optic nerve and spinal cord. The trial is specifically enrolling adults in China who have had recent disease activity.
This study tests a medicine called ravulizumab to see if it lowers certain proteins in the blood that may indicate nerve damage in people with NMOSD. If you have NMOSD, this study could help track how well the treatment works.
This study looks at how well ravulizumab works for people with generalized myasthenia gravis (gMG) who have not tried complement inhibitors before. The goal is to see if this treatment helps improve symptoms in everyday life.
This study looks at how well patients with aHUS in Poland are doing after treatment with ravulizumab (Ultomiris). It is for people who have already received this drug through the national program and agree to share their health information.
This trial compares several medications to see which works best for NMOSD, an autoimmune disease that can cause vision loss and paralysis. You must have a specific antibody (AQP4-IgG) to join.
Hear when a new Neuromyelitis Optica trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.